Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 26;24(1):96. doi: 10.1186/s10194-023-01628-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Inhibition of Panx1 channels prevents the CSD-related acute (at 30 min) elevation of MGS scores, oculotemporal (OT) (head grooming) strokes, and cortical nuclear HMGB1 release. A Pre-treatment of WT mice with Panx1 channel inhibitor TAT-Panx₃₀₈ (i.p. administration 30 min prior to the start of optogenetic stimulation) prevented the elevation of MGS scores at 30 min following CSD, compared to mice pre-treated with scrambled (control) protein (TAT-Panx_sc). B TAT-Panx₃₀₈ pre-treatment prevented the increase of strokes at 30 min following CSD, compared to control TAT-Panx_sc administration. C TAT-Panx₃₀₈ pre-treatment prevented the increase nuclear HMGB1 release in both the ipsi- and contralateral to somatosensory cortex, compared to control TAT-Panx_sc administration. D Representative photomicrographs of ipsilateral somatosensory cortex of WT mice 30 min after CSD, pretreated with TAT-Panx₃₀₈ or TAT-Panx_sc, stained for HMGB1 (red; nuclear Hoechst staining in blue). * p < 0.05. Scale bar: 250 μm